Phreesia price target lowered to $14 from $32 at BMO Capital

BMO Capital analyst Sean Dodge lowered the firm’s price target on Phreesia (PHR) to $14 from $32 and keeps an Outperform rating on the shares. The company’s Q4 update was disappointing, with management lowering its FY27 revenue outlook 6.7% on a temporary disruption within its Network Solutions pharma ad end-market, though on the bright side, Phreesia believes these disruptions are not widespread and is aggressively rolling out efficiency initiatives that should be sufficient to offset all the impact, the analyst tells investors in a research note.